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Abstract
The carboxy-terminal domain (CTD) of the largest subunit (RPB1) of RNA polymerase II (RNAP-II) is essential for gene
expression in metazoa and yeast. The canonical CTD is characterized by heptapeptide repeats. Differential phosphorylation
of canonical CTD orchestrates transcriptional and co-transcriptional maturation of mRNA and snRNA. Many organisms,
including trypanosomes, lack a canonical CTD. In these organisms, the CTD is called a non-canonical CTD or pseudo-CTD
(YCTD. In the African trypanosome, Trypanosoma brucei, the YCTD is ,285 amino acids long, rich in serines and prolines,
and phosphorylated. We report that T. brucei RNAP-II lacking the entire YCTD or containing only a 95-amino-acid-long
YCTD failed to support cell viability. In contrast, RNAP-II with a 186-amino-acid-long YCTD maintained cellular growth.
RNAP-II with YCTD truncations resulted in abortive initiation of transcription. These data establish that non-canonical CTDs
play an important role in gene expression.
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Introduction
RNA polymerase II (RNAP-II) is the eukaryotic enzyme
responsible for synthesis of mRNA. This enzyme is an
,550 kDa complex consisting of twelve subunits, RPB1-12 [1].
The carboxy-terminal domain (CTD) of the largest subunit,
RPB1, is essential for cell survival. In well-studied organisms, such
as metazoa and yeast, the CTD consists of consensus heptapeptide
repeats having the sequence Y1S2P3T4S5P6S7 ([2,3] and reviewed
in [4,5]). The CTD plays a pivotal role in RNA production by
recruiting multiple proteins that modulate transcription initiation,
transcription elongation, transcription termination, co-transcrip-
tional mRNA 59 capping, RNA splicing, and RNA polyadenyl-
ation [6–8]. Interaction of proteins with the CTD is orchestrated
by dynamic and differential phosphorylation. The patterns of
phosphorylation make up the ‘‘CTD code’’ [5,9]. Non-canonical
CTDs, which lack the heptapeptide repeats and thus are pseudo
CTDs (YCTDs), exist in a wide variety of eukaryotic organisms
[10,11]. For example, the early branching protozoan, Trichomonas
vaginalis, and the multicellular red alga, Bonnemaisonia hamifera,a s
well as members of the Apicomplexian, Stylonichia, and
Kinetoplastid groups contain YCTDs as part of their RNAP-II
machinery [12,13]. We sought to determine whether a YCTD is
essential for gene expression.
Among the Kinetoplastids, the largest subunit of RNAP-II has
an ,300 amino acid-long YCTD that lacks heptapeptide repeats
and exhibits little amino acid similarity to CTDs of other
organisms [14–17]. In the African trypanosome, Trypanosoma
brucei, the YCTD of RNAP-II is an ,285 amino acid-long
carboxyl terminal extension of RPB1 (Figure 1 and [15,16]). In T.
brucei, RNAP-II synthesizes two very different types of RNA, a
long polycistronic precursor mRNA (pre-mRNA) and a short,
capped Spliced Leader (SL) RNA. mRNA maturation require
addition of SL RNA to pre-mRNAs through a trans-splicing
reaction. Different forms of RNAP-II, associated with specific
transcription factors, likely transcribe SL RNAs and pre-mRNAs.
Indeed the T. brucei homolog of the yeast transcription factor Spt16
appears to associate with protein-coding genes but not with the SL
RNA gene [18]. In contrast, the T. brucei homolog of the
mammalian snRNA transcription factor SNAPc appears to
associate only with the SL RNA gene promoter, although one
subunit of SNAPc in Leishmania major, a relate parasite, occupies
regions upstream of protein-coding genes [19]. Whether RNAP-II
YCTD is important for transcription of either the SL RNA gene
and/or protein-coding genes is unknown.
To address if non-canonical CTDs play a fundamental role in
gene expression, we undertook a study of T. brucei RNAP-II
YCTD. We altered RNAP-II and tested its function using an in
vivo assay system and discovered that the YCTD is essential for
cell survivial and production of both SL RNA and mRNA.
Nascent transcription analysis demonstrated that the YCTD is
required specifically for productive transcription initiation, as an
RNAP-II severely truncated within the YCTD caused abortive
initiation. These results demonstrate that a non-canonical CTD
is a vital component of the RNAP-II machinery in eukaryotic
cells.
Results
T. brucei YCTD undergoes phosphorylation
It has been shown previously that T. brucei RNAP-II is modified
by phosphorylation, despite the lack of consensus heptapeptide
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occurs within the YCTD, we directly visualized RNAP-II labeled
with
32P-orthophosphate. For this work, we tagged RNAP-II in a T.
bruceiprocycliccellline by stably-expressing the RPB3subunitof the
enzyme with a tandem affinity tag. These transgenic cells were
metabolically labeled with
32P-orthophosphate and RNAP-II was
Figure 1. The YCTD of T. brucei RNAP-II lacks conserved heptapeptide sequence motifs found in most other eukaryotes. (A) Domain
structure of T. brucei RPB1 showing the presence of the characteristic A–H domains and the divergent carboxy-terminal domain. The carboxy
terminus of T. brucei RPB1 lacks the highly conserved YSPTSPS repeats that orchestrate multiple co-transcriptional processes in the well-studied
eukarya. Four different RPB1 proteins analyzed in this study are diagrammed: RPB1 containing no YCTD (DYCTD, truncated at amino acid 1481), one-
third of YCTD (1/3 YCTD, truncated at amino acid 1576), two-thirds of YCTD (2/3 YCTD, truncated at amino acid 1667), and full length YCTD (full
YCTD). The heavy line at the C-terminus of each truncation represents the five conserved amino acids (E/DEEEQ). The location of the ,27 kDa Lys-C
fragment is indicated with a horizontal line over the YCTD. (B) Alignment of the human and yeast CTD with the YCTD sequence of T. brucei RPB1. A
portion of the H domain is included (gray bar) as reference. The CTD’s linker region (thin line) and the heptapeptide repeat domain (thick line) are
shown. Thirty-one of the 52 heptapeptide repeats in the mammalian CTD are shown. The YCTD truncations are defined by arrows following the final
amino acid contained in each mutant protein. Grey boxes show similar amino acids in two sequences, black boxes show similar amino acids in all
three sequences.
doi:10.1371/journal.pone.0006959.g001
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binding peptide affinity chromatography. An autoradiograph of the
purified protein, separated into polypeptides by denaturing gel
electrophoresis,indicated thatthelargestsubunit(RPB1)ismodified
by phosphorylation (Figure 2A). A stained gel of the purified
proteins revealed both phosphorylated and non-phosphorylated
forms of RPB1 (Figure 2B). Seven of the eleven other RNAP-II
subunits, as verified by mass spectrometry, were also seen [21]. To
determine whether phosphorylation occurs in the YCTD of RPB1,
32P-labeled RPB1 was subjected to in-gel proteolysis by endopro-
teinase Lys-C, which cleaves the peptide bond at the carboxy side of
lysine. Lys-C digestion of RPB1 generated a 253 amino acid long,
,27 kDa, peptide consisting only of the YCTD (from amino acid
1491–1744) minus its terminal 21 amino acids (Figure 1A). The
remainder of RPB1 was fragmented into ,76 amino acid-long
peptides. Immunoblotting with anti-YCTD antibodies detected the
,27 kDa peptide (Figure 2C). Lys-C digestion products from
32P-
orthophosphate-labeled RPB1 are shown in Figure 2D. The
heterogeneous collection of radiolabeled peptides migrating more
slowly than ,27 kDa are YCTD peptides that differ in
phosphorylation patterns. The immunoblot in Figure 2C shows
most clearly the non-phosphorylated YCTD because the phos-
phorylated peptides migrate as a broad band that eludes antibody
detection. Thus, our analysis demonstrates that although T. brucei
RNAP-II YCTD lacks a heptapeptide repeat sequence, it under-
goes phosphorylation.
RNAi-targeting of mRNA 39UTR allows regulated
depletion of RPB1
To test directly the importance of RNAP-II YCTD in
transcription, we used RNAi to deplete endogenous RNAP-II
(referred to as ‘endo’) and replace it with mutant RNAP-II,
conditionally expressed from an exogenously provided DNA
cassette. Endo RNAP-II relies upon RPB1 that is encoded by two
sets of allelic gene copies on chromosomes 4 and 8. These genes
differ slightly in their protein-coding regions. Fortunately, RPB1
mRNAs generated from all four alleles contain identical 39UTRs,
as determined by analysis of RPB1 mRNA by 39 RACE-PCR
(data not shown). We generated cell lines containing inducible
RNAi that targeted the RPB1 39UTR. As expected, targeting
39UTR of RPB1 mRNA by tetracycline-inducible RNAi expres-
sion stops cellular growth of procyclic T. brucei by day 2, in contrast
to uninduced cells. The induced cells progressed to cell death by
day 4 (Figure 3A). Western analysis of total cellular protein showed
decrease in RPB1 beginning by day 1 (Figure 3B).
RNAP-II containing 1/3 YCTD is toxic and causes cell
death
To study whether RPB1 mutant proteins can support
transcription, we expressed tagged versions of full, 2/3, 1/3 and
null (D) YCTD domain-containing proteins (Figure 1A). The full
YCTD or 2/3 YCTD RPB1 transgenic cell lines were readily
established. However, cell lines with a 1/3 YCTD or DY CTD
Figure 2. The YCTD of T. brucei RNAP-II undergoes phosphorylation. (A) RNAP-II tandem affinity purified from RPB3-tagged cells
metabolically labeled with
32P-orthophosphate was separated on SDS-8% PAGE and autoradiographed.
32P-labeled RPB1 (RPB1-*PO4) is shown (right
lane). The left lane contains a similar purification from A7-tagged cells and served as a control for protein purification[21]. (B) Eight of the twelve
subunits of RNAP-II are shown on silver-stained SDS-8% PAGE. The two RPB1 bands were confirmed as the phosphorylated and non-phosphorylated
forms of RPB1 (II0 and IIA) by the conversion of II0 to IIA after lambda protein phosphatase treatment. II0 and IIA were detected using anti-YCTD
antibody (Daniels J-P, Wickstead, W and Gull, K, personal communication). Asterisks mark four yet to be identified polypeptides. (C) A Western blot
using anti-YCTD antibodies identified the ,27 kDa as in-gel digestion product of RPB1 with endoproteinase Lys-C. The input (left lane) was RPB1
prior to proteolysis. (D) An autoradiograph that contains the YCTD (YCTD -*PO4, right lane), generated by in-gel digestion of RPB1-*PO4 with Lys-C.
The YCTD-*PO4 migrates more slowly than the unmodified peptide and is broad band probably because it contains a heterogeneous number of
modifications. The input (left lane) was RPB1-*PO4 prior to proteolysis.
doi:10.1371/journal.pone.0006959.g002
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construct was obtained after multiple transfections. The 1/3
YCTD or DY CTD RPB1-containing parasites grew poorly and
had low levels of non-phosphorylated tagged-RPB1 (Figure S1).
These results indicated that expression of either the 1/3 YCTD or
DY CTD poison cells and prohibit selection of robustly expressing
cell lines.
To investigate whether 1/3 YCTD poisons the RNAP-II
enzyme, we tailored RPB1 transgenes to express in an inducible
fashion (Table 1). The discovery that RNAP-II with 2/3 YCTD
was well tolerated and modified by phosphorylation (Figure S1),
whereas 1/3 YCTD was not, prompted us to compare 2/3
YCTD with 1/3 YCTD RNAP-II in our studies. Induced
expression of 2/3 YCTD RNAP-II resulted in normal cellular
growth (Figure 4A). However, induced expression of 1/3 YCTD
RNAP-II was toxic to cells. The crippling effect of 1/3 YCTD
RNAP-II was evident in the rapid growth arrest and loss of viable
cells. Microscopic observation following expression of 1/3 YCTD
RNAP-II revealed striking changes: cells became rounded and
formed large aggregates. In contrast, cell morphology was normal
following expression of RNAP-II with 2/3 YCTD (Figure 4A).
To verify that the 1/3 YCTD RPB1 was incorporated into
RNAP-II, we analyzed enzyme complexes (Figure 4B). Fraction-
ation of nuclear extract by sucrose density-gradient centrifugation
confirmed that tagged-2/3 YCTD and tagged-1/3 YCTD RPB1
assembled into complexes that migrated near the bottom of the
gradient. These same fractions were enriched for endogenous
RNAP-II. Transcriptionally active endogenous RNAP-II also
migrated at this position in similar sedimentation velocity
measurements (data not shown). Western blot analysis of
immunoprecipitated proteins captured by polyclonal anti-RPB4
antibody demonstrated the presence of tagged-1/3 YCTD,
tagged-2/3 YCTD, or endogenous RPB1 in RNAP-II
(Figure 4C). These results confirmed that 2/3 YCTD or 1/3
YCTD RPB1 were incorporated into RNAP-II. Thus, RNAP-II
with 1/3 YCTD is toxic to cells and produces a dominant
negative effect over endogenous RNAP-II.
RNAP-II containing 2/3 YCTD rescues cellular growth in
absence of endogenous YCTD
Although a 1/3 YCTD RNAP-II had a dominant-negative
effect, cells expressing both full-length YCTD and 2/3 YCTD
RNAP-II grew normally. We speculated that RNAP-II harboring
a 2/3 YCTD might be as proficient as the endogenous enzyme in
supporting cell growth. Thus, a 2/3 YCTD RNAP-II was tested
for its ability to rescue cells depleted of endogenous RNAP-II
(Figure 5). We established stable cell lines containing a regulated
RNAi construct and a regulated tagged-RPB1 gene. Addition of
tetracycline induced RNAi production and tagged RPB1 expres-
sion. Thus, endogenous RPB1 was selectively destroyed and the
tagged-RPB1 proteins that contain either the 2/3 YCTD or 1/3
YCTD were produced. Growth curves showed that 2/3 YCTD
RNAP-II sustained cellular growth after RNAi-depletion of
endogenous RPB1 (Figure 5A). In contrast, 1/3 YCTD RNAP-
II failed to rescue the cells.
Endogenous RPB1 depletion was monitored by immunoblotting
with anti-YCTD antibody. The top, left blot in Figure 5B shows
that both phosphorylated and non-phosphorylated forms of the
endogenous RPB1 decreased after RNAi-targeting. In addition,
both phosphorylated and non-phosphorylated forms of the tagged-
2/3 YCTD RPB1 were present after induction. Similar results are
shown in the top, right blot in Figure 5B, although the diminished
number of epitopes on the 1/3 YCTD resulted in weak antibody
detection. Expression of tagged proteins was independently
monitored in immunoblots by using anti-tag antibodies
(Figure 5B, lower blots). As noted above, the 1/3 YCTD RPB1
failed to undergo phosphorylation, and thus a single band
corresponding to the tagged protein was observed. These data
confirmed that induced expression of tagged 2/3 and 1/3 YCTD
RPB1 occurred in our experiments. Taken together, these results
argue that YCTD contributes to cell viability, likely as an essential
component of functional RNAP-II.
Figure 3. Depletion of RPB1 by RNAi causes lethality. (A) Growth curves of a clonal transgenic RNAi-containing cell line in the presence (black
squares) and absence (gray squares) of tetracycline. Tetracycline was added on day 0. (B) Western analysis of whole cell lysates prepared on days 0–4
after RNAi induction, using anti-YCTD antibodies, shows depletion of T. brucei RPB1. Loading controls are in the lower panel.
doi:10.1371/journal.pone.0006959.g003
Table 1. RPB1 expression schemes for YCTD analysis.
2Tet +Tet
Endogenous RPB1 On On Fig. 4
Inducible tagged-RPB1 Off On
Endogenous RPB1 On Off Fig. 5–7
Inducible tagged-RPB1 Off On
doi:10.1371/journal.pone.0006959.t001
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PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e6959Figure 4. RNAP-II with a 1/3 YCTD poisons cell growth. (A) Growth curves of transgenic T. brucei cell lines in the presence (black, on) or
absence (gray, off) of either 2/3 YCTD (left panel, square) or 1/3 YCTD RPB1 (right panel, circle). Western analyses of whole cell lysates before (off)
and two days after (on) induction of exogenous RPB1 are shown. Microscopic images of cellular morphology two days post-induction of exogenous
proteins are shown. (B) Western analyses of 10 to 30% sucrose gradient fractions. Both endogenous T. brucei RPB1 (top panel, endo) and exogenous
RPB1 (bottom panel, tagged) are shown. (C) Immunoblot analysis of whole cell extract (left three lanes, Extract) or anti-T. brucei RPB4 immune-
captured proteins (right three lanes, a-RPB4) from wild-type (WT) and transgenic parasites expressing exogenous 2/3 YCTD or 1/3 YCTD RPB1.
doi:10.1371/journal.pone.0006959.g004
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transcript levels
To determine the role of YCTD on RNAP-II transcription, first
we analyzed transgenic cells for steady-state transcript levels
following concomitant endogenous RPB1 depletion and tagged-
RPB1 induction. Northern blot analyses of total RNA confirmed
that expression of the tagged-RPB1 mRNA from transgenes
containing either the 2/3 YCTD or 1/3 YCTD was tightly
regulated and induced with tetracycline (Figure 6A). These data
are shown schematically in the right portion of the panel. Levels of
7SL RNA, which requires RNAP-III, were unaffected during the
two-day course of the experiment. In contrast, levels of b-tubulin
mRNA, which requires RNAP-II for synthesis, were markedly
reduced in cells expressing the 1/3 YCTD RNAP-II; only ,40%
of the b-tubulin mRNA remained by day 2 after induction. In cells
containing 2/3 YCTD RNAP-II, no decrease in b-tubulin mRNA
was observed. The differential effect on b-tubulin levels supported
the observation that while RNAP-II with 1/3 YCTD was
crippled, RNAP-II with 2/3 YCTD was functional. Finally, levels
of procyclin/EP1 mRNA, which requires RNAP-I, indicated that
,60% of the procyclin/EP1 mRNA was present in 1/3 YCTD-
expressing cells in comparisons to cells expressing endogenous
enzyme. The decrease in EP1 mRNA steady-state levels was likely
due to inefficient mRNA maturation, which requires the RNAP-
II-dependent SL RNA transcript.
To test this prediction, we assessed SL RNA levels by primer
extension analysis (Figure 6B). Cells that relied on 1/3 YCTD
RNAP-II exhibited a striking decrease in SL RNA steady-state
levels; there was a 70% decrease on day 1 and a 85% decrease by
day 2. In contrast, cells containing 2/3 YCTD RNAP-II
maintained SL RNA levels. They experienced only a ,30%
decrease on day 1 that did not change by day 2. Thus, 1/3 YCTD
RNAP-II was probably incapable of making new SL RNA
transcripts and thus failed to maintain a reservoir of SL RNA
necessary for efficient mRNA maturation.
RNAP-II with 1/3 YCTD is defective in transcription and
causes abortive initiation
To examine how the 1/3 YCTD impairs RNAP-II function, we
assessed nascent RNA synthesis in transgenic cells before and after
expression of 1/3 YCTD RPB1-containing enzyme. In compar-
ison to uninduced cells, cells utilizing 1/3 YCTD RNAP-II poorly
synthesized b2tubulin and SL RNA (Figure 7A). Reduced
synthesis of b2tubulin and SL RNA was also observed in cells
Figure 5. RNAP-II with a 2/3 YCTD supports cell growth, whereas enzyme with a 1/3 YCTD does not. (A) Growth curves of T. brucei RNAi
cell lines in the presence (black squares and circles) or absence of tetracycline (gray squares and circles). Tetracycline causes RNAi-dependent knock
down of endogenous RPB1 and induction of exogenous RPB1. 2/3 YCTD RPB1 is in the left panel, 1/3 YCTD RPB1 is in the right panel. (B)
Immunoblot of whole cell lysates from cultures shown in (A) after tetracycline induction for 0–3 days. Endogenous and exogenous RPB1 were
detected as in Figure 4. The four bands in the left upper portion are the phosphorylated and non-phosphorylated forms of the endogenous and 2/3
YCTD RBP1 proteins. The upper right panel displays three bands as the 1/3 YCTD RPB1 is not phosphorylated.
doi:10.1371/journal.pone.0006959.g005
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was minimal. For the cells relying on the 1/3 YCTD RNAP-II, we
observed an overall decrease in RNAP-I (procyclin/EP1 and 18S
rRNA) and RNAP-III (7SL RNA and 5S rRNA) transcription,
which probably indicates a general reduction in their transcrip-
tional capacity.
We verified that the 1/3 YCTD RNAP-II is less efficient in
transcription than its wild-type or 2/3 YCTD-containing homolog
by direct visualization of newly synthesized, radiolabeled SL RNA
(Figure 7B). Nascent SL RNA was significantly more reduced in
cells containing 1/3 YCTD RNAP-II compared to cells containing
2/3 YCTD RNAP-II (,60% compared to 20%), after two days of
expression. Interestingly, we also observed an increase in small
radiolabeled molecules migrating near the bottom of the gel, as
shown in the brief exposure in Figure 7B. Compared to wild-type,
cells expressing either 2/3 YCTD RNAP-II or 1/3 YCTD RNAP-
II produced increased level of very short (,4 nt long) transcripts.
The amount of short transcripts was greater in cells containing 1/3
YCTD RNAP-II (eight-fold over wild-type) than in cells containing
2/3 YCTD (four-fold over wild-type). We postulate that these
RNAs were generated from abortive initiation.
We first determined that the radiolabelled molecules were RNA,
and thus sensitive to alkali treatment (Figure 7C). Mononucleotides
were produced from gel-purified, short transcripts (see Figure 7B,
brief exposure). To confirm that the short RNAs indeed originated
from transcription initiation events, we characterized their 59 end.
Short transcripts, treated with Tobacco Acid Pyrophosphatase
(TAP), were ligated to form a ladder of longer RNAs (Figure 7D).
No ligation products were observed when TAP-treatment was
omitted. Taken together, the nascent transcription experiments
supported the conclusion that RNAP-II requires a YCTD to enter
into a productive transcription process.
Discussion
The present work describes the first characterization of an
RNAP-II non-canonical CTD, which is found in many single- cell
organisms. The T. brucei RNAP-II uses a non-canonical CTD for
cell growth and viability. The growth defect associated with
YCTD deletions was likely a direct result of decreased mRNA
production. Specifically, when the YCTD is truncated, defective
RNAP-II produced less mRNA and SL RNA and increased
abortive initiation products.
A consequence of a non-canonical CTD is the opportunity for
RNAP-II to partner with unknown proteins. This contention is
best illuminated by the elegant biochemical and structural studies
in Trichomonas vaginalis. Here, a non-canonical CTD partners with
a Trichomonas-specific protein, IBP39, to stably assemble RNAP-II
at the initiator element of promoters [12]. Affinity-purification of
RNAP-II from T. brucei revealed several copurified proteins that
appear to be trypanosome-specific [21,22]. We speculate that
some of these proteins participate in gene expression through
specific interaction with YCTD. Indeed, a ten amino acid motif
(SSYHLQ-SVAP) is shared among trypanosomes within the
serine/proline-rich subdomain of YCTD (Figure 1). This motif
is within the 2/3 YCTD truncation that rescued cells when wild-
type RNAP-II was depleted (Figures 5 and 6). In summary, these
observations are consistent with non-canonical CTD having
significant roles in organism-specific RNAP-II machineries.
Modification of canonical CTD by phosphorylation at specific
serine residues is required for orchestrating transcriptional
activities in better studied eukaryotes. It is known that a S5
phospho CTD-code dictates that an enzyme leaves a preinitiation
complex, and a S2 phospho CTD-code dictates that an enzyme
becomes elongation competent [6]. In T.brucei, we found
phosphorylated forms of YCTD within RNAP-II (Figure 2).
Proteolytic digestion of phospho-YCTD produced what was most
likely a heterogeneous set of differentially phosphorylated YCTDs.
We note that there are ,30 potential phosphorylation sites within
the 2/3 YCTD that are absent from the 1/3 YCTD. Thus, we
speculate that a phosphorylation-code occurs within the YCTD in
T. brucei that may account for the two different RNAP-II-
dependent reactions, namely, transcription of short, capped SL
RNAs and long pre-mRNAs. Such a YCTD code may allow
RNAP-II to specifically function at the SL RNA gene promoter,
much like the S7 phosphorylation mark on the mammalian CTD
directs polymerase specifically during small nuclear RNA
transcription [4].
The structure of the canonical CTD is divided into three
subdomains: the linker region, the central reiterated region that
Figure 6. RNAP-II requires a 2/3 YCTD to maintain steady-state levels of SL RNA and mRNA. (A) Northern blot analysis of total RNA
prepared from wild-type (WT) and transgenic T. brucei cell lines before (day 0) and after 1 and 2 days following RNAi-dependent knock down of
endogenous T. brucei RPB1 and induction of exogenous 2/3 YCTD or 1/3 YCTD RPB1. Ribosomal RNAs (rRNAs) were visualized by ethidium bromide
staining. Transgene-derived RPB1 mRNA, b-tubulin mRNA, EP1 mRNA, and 7SL RNA were visualized by hybridizing with specific radiolabelled
oligonucleotides. b-tubulin and EP1 mRNA levels were normalized using 7SL RNA and considered 100% on day 0. Transgene-derived RPB1 mRNA is
indicated as 100% on day 1. (B) SL RNA was analyzed by primer extension of RNA from cells expressing RPB1 as in (A). Radiolabelled oligonucleotides
hybridized to either SL RNA or U2 snRNA in the primer extension. A line graph shows percent SL RNA with respect to U2 snRNA after two days of
tetracycline induction. Day 0 is considered 100%. A representative experiment from three independent experiments is shown.
doi:10.1371/journal.pone.0006959.g006
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terminal short acidic peptide [23]. The YCTD parallels the CTD
in structure; it contains a linker region of size similar to CTD, a
central serine/proline-rich region, and a terminal short acidic
peptide (Figure 1). In the case of 1/3 YCTD, the RNAP-II
contained a YCTD having only the linker region plus a small part
of the central serine/proline-rich region. This enzyme failed to
rescue cell growth when wild-type RNAP-II was depleted. In
addition, we did not observe phosphorylation of the 1/3 YCTD.
In contrast, 2/3 YCTD of RNAP-II contained the linker region
plus half of the central serine/proline-rich region. This enzyme
was phosphorylated within the YCTD and allowed cell growth in
the absence of wild-type RNAP-II. Taken together, it appears that
the central serine/proline-rich region of the YCTD is important
for polymerase function.
Although 2/3 YCTD could sustain cell growth, it generated
increased levels of abortive transcripts. Nascent transcription in
cells containing the 1/3 YCTD generated even higher levels of
abortive transcripts. These transcripts were confirmed to be
abortively initiated RNA, as they possessed 59 tri-phosphate ends,
a signature of transcription initiation (Figure 7B, C and D). Studies
of the mammalian CTD indicate that an RNAP-II having only 5
heptapeptide repeats can bind a gene promoter but is defective in
initiating transcription [24]. This mutant CTD is structurally
similar to our 1/3 YCTD, because it contains the linker region, a
very small part of the central region, and the terminal acidic
region. Thus, the central region of both the YCTD and CTD
plays a role in the transition from an initiating polymerase, which
generates abortive RNAs, to an elongating enzyme, which
produces full- length mRNAs.
An unexpected and interesting observation was made when an
RNAP-II with 1/3 YCTD was expressed in cells along with wild-
type levels of endogenous RNAP-II. Within 16 hours of 1/3
YCTD expression, cells ceased to move, changed their shape,
formed large aggregates, and soon died (Figure 4A). These
dramatic phenotypic changes were not observed when 1/3 YCTD
Figure 7. RNAP-II with 1/3 YCTD is impaired in synthesizing SL RNA and pre-mRNA and produced abortive initiation. (A) Analysis of
nascent RNA prepared from cells, as in Figure 6, before (day 0) and 2 days after tetracycline induction. PCR-generated DNAs for the indicated genes
were immobilized on nylon membrane and hybridized with radiolabelled nascent RNA prepared from permeabilized cells. A line diagram indicates
the changes in nascent RNA, as measured by densitometric analysis of slots from two independent experiments, and normalized to the pUC19
hybridization signal. * marks RNAP-II-transcribed SL RNA (black square), b-tubulin (gray square) and the SL RNA downstream region (open square).
RNAP-I-transcribed EP1 (black circle), 18S rRNA (open circle), and RNAP-III-transcribed 7SL RNA (open triangle) and 5S rRNA (black triangle), are also
shown. Day 0 is indicated as 100%. (B) Nascent SL RNA, from wild-type (WT) and transgenic T. brucei cells before (day 0) and after 1 and 2 days of
exogenous RPB1 expression as in (A) were analyzed by denaturing 8% PAGE. Labeled SL RNA and tRNA are shown. Increasing amounts of short
transcripts, (rN)n#4, are produced in permeabilized cells expressing the 1/3 YCTD RNAP-II. The short transcripts are evident in the brief exposure.
Nascent SL RNA levels with respect to tRNA levels are indicated on the left y-axis. Day 0 is indicated as 100%. The increase in short transcripts before
(day 0) and after 1 and 2 days after RPB1 expression is shown on the right y-axis. Fold increase was always compared to the wild-type level. Markers
are shown in the leftmost lane of the gel. (C) Analysis of the short transcripts produced in permeabilized cells expressing 1/3 YCTD RNAP-II on day 2
of tetracycline induction. Radiolabelled mononucleotides were produced by alkali hydrolysis of the gel-purified short transcripts, identifying them as
RNA. Markers (lanes 1 and 2) and
32P-UTP (lane 3) are shown on the gel. (D) The short transcripts, when treated with TAP followed by RNA ligase,
formed larger RNAs by self-ligation (lanes 4 and 7). Larger RNAs were not detected in the absence of TAP enzyme (lanes 3 and 6), indicating the
presence of a tri-phosphate group at the 59 end of the short transcripts. Lanes 2 and 5 contain the input (eluted) RNA. Marker is shown in lane 1.
doi:10.1371/journal.pone.0006959.g007
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RNAP-II. In this case cells merely stopped dividing by day 2 and
slowly died (Figure 5A). This differential response may indicate
that a wild-type RNAP-II, is required to synthesize protein-coding
RNAs used in a stress response [25]. A stress response may
account for the observed, abrupt morphological alterations in the
cells expressing both the mutant and the endogenous polymerase.
An actively transcribing polymerase in cells with abundant wild-
type RNAP-II enables cells to respond to the stress imposed by the
mutant YCTD. In contrast, cells with limited number of active
polymerase could not. Indeed, Drosophila stress responses require
transcription of heat shock proteins within minutes of the initial
stress [26]. This rapid response is accompanied by the release of
RNAP-II from its transcriptionally paused state on heat shock
genes and depends on transcription elongation factors [27]. If a
mechanism similar to this type of elongation control exists in
trypanosomes, it raises the intriguing possibility of RNAP-
II transcriptional control, heretofore unrecognized, in these
organisms.
Materials and Methods
Plasmid constructs
The RNAi construct was made in p2T7-177 by inserting a
260 bp region of the RPB1 39UTR at BamHI and XhoI sites [28].
This plasmid integrates in the highly repressed 177 bp satellite
region of a mini-chromosome. The construct was linearized with
NotI, transfected into procyclic T. brucei cells and transgenic clonal
cell lines selected by limiting dilution in the presence of
phleomycin [29].
pAD71, designed to express a transgene constitutively, was
derived from pUC19 and contains sequences for homologous
recombination into the procyclin/GPEET locus, following
linearization by NotI digestion. The transgene uses the endogenous
procyclin/GPEET promoter and a 39UTR derived from the
aldolase mRNA. A blasticidin–resistance gene, which follows the
transgene, is co-expressed using actin 59 SAS and 39UTR regions.
pAD74 was derived from pLEW100, minus the luciferase open
reading frame and containing a blasticidin-resistance gene in place
of the phleomycin-resistance gene and an rRNA promoter in place
of the procyclin/GPEET promoter.
Plasmid RPB3-SBP was generated by joining the RPB3 open
reading frame (Tb927.3.550) with the protein A open reading
frame and the Streptavidin binding protein (SBP) open reading
frame (a gift from Larry Simpson) and cloned into pAD71
downstream from the procyclin/GPEET 59UTR. To establish
mutant RNAP-II, we generated epitope tagged versions of RPB1,
with varying truncations of YCTD. A Ty1-tag (EVHTNQDPLD)
[30] at the N-terminus allowed us to monitor the expression of
mutant RPB1 proteins. Transgenes expressing mutant RNAP-II
were designed with a well-characterized 39UTR of aldolase (ALD)
mRNA and thus resistant to the RNAi-targeting of endogenous
RPB1 mRNA. The C-terminal five conserved amino acids, which
contribute to RPB1 stability [24], was included in each of the four
transgene constructs (Figure 1A). For constitutive expression of the
transgenes, the tagged and mutant RPB1 ORFs were cloned into
pAD71. For inducible expression of the transgenes, they were
cloned into pAD74. All plasmid constructs were confirmed by
DNA sequencing.
Culturing and transfection of parasites
Procyclic (tsetse midgut form) wild-type T. brucei Lister 427 was
grown in SDM-79 supplemented with 10% FCS as described [29].
For all transgene experiments, cells were selected and grown in
medium containing tetracycline-free serum. The 29–13 cell line
contains the T7 RNAP and the tetracycline repressor that are
maintained by their co-expression with G418 and hygromycin-
resistance genes [29]. p2T7-177 derivatives were transfected into
29–13 and stable cell lines were selected using 2.5 mg/ml
phleomycin. pAD71 and pAD74 derivatives were transfected into
29–13 and selected using 10 mg/ml blasticidin. Inducible RNAi
and transgene expression were regulated by addition of 500 ng/ml
tetracycline. For metabolic labeling, 5610
8cells were incubated
with 500 mCi of
32P-orthophosphate (9000 Ci/mmole) in 5 mls of
phosphate-free DMEM (40 min, 26uC).
Preparation of T. brucei nuclear extracts and protein
purification
Nuclear extracts were made from the RPB3-SBP cells as
previously described [31]. Protein was purified using tandem
affinity chromatography; IgG-bound protein was washed and
released from the matrix using TEV-protease. Eluted protein was
bound to Streptavidin-agarose, washed and eluted with 2 mM
biotin-containing buffer. For velocity sedimentation, nuclear
extracts were loaded onto a 10-30% sucrose gradient as described
[31]. Fractions were collected from the bottom of the tube and
analyzed by immunoblotting.
32P-containing RPB1 was in-gel
digested with endoproteinase Lys-C (Roche) as recommended by
the manufacturer.
Antibodies and western analyses
Polyclonal anti-YCTD antibody, produced in rabbits, recog-
nizes endogenous RPB1 as well as the full-length, 2/3, and 1/3
YCTD RPB1 derived from transgenes. All four transgene-derived
tagged-RPB1 proteins are also detected with monoclonal anti-Ty1
antibody, generated in the Gull laboratory and kindly provided by
the Cross laboratory [30]. Anti-RPB4 antibody, produced in
rabbits from recombinant protein as antigen, was used for
immunoprecipitation experiments. For immunoprecipitations,
nuclear extracts were incubated with anti-RPB4 antibody bound
to protein A-sepharose, washed in buffer (20 mM Hepes [pH 7.9],
150 mM KCL, 150 sucrose, 2.5 mM MgCl2, 1 mM EDTA,
2.5 mM DTT, 0.1%NP-40, 1 mM each of pepstatin A, leupeptin,
and PMSF) and analyzed by immunoblotting using ECL
TM kit
from Amersham.
RNA analysis
Total cellular RNA from wild-type and transgenic cells was
prepared using Trizol
TM reagents. For Northern analysis, 5 mgo f
total RNA was separated on a formaldehyde-1.2% agarose gel in
MOPS buffer [32]. RNA was fragmented by alkali-treatment,
transferred to nylon membranes and hybridized with
32P-labelled
oligonucleotides. Steady-state SL and U2 RNA levels were
determined by primer extension analysis, using
32P-labeled
oligonucleotides complementary to these RNAs. Nascent RNA
was synthesized in lysolecithin-permeabilized cells using
32P-UTP
[33] and profiled on 7M urea 10% polyacrylamide gel. Short
transcripts were extracted from the gel, purified according to [34]
and resolved on a 7M urea 25% polyacrylamide gel. Tobacco acid
pyrophosphatase (Epicentre) and T4 RNA ligase (New England
Biolabs) were used according to manufactures’ protocols. Data
were captured on a Typhoon PhosphorImager
TM and quantifica-
tion was performed using ImageQuant
TM software.
Microscopy
An Olympus BX61 microscope with Nomarski DIC optics was
used to visualize live cells.
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Alignments of RPB1 from T. brucei, human (P24928;
Nc_000017.9), and Saccharomyces cerevisiae (YDL140C) were
performed using CLUSTALW [35]. Results were manually
altered to optimize comparisons and were represented using
GeneDoc (http://www.psc.edu/biomed/genedoc).
Supporting Information
Figure S1 Expression of RPB1 proteins with either 1/3 yCTD
or delta- yCTD inhibits T. brucei cellular growth. (A) Growth
curves of transgenic cell lines constitutively expressing a tagged
full-length yCTD (black square), 2/3 yCTD (gray square), 1/3
yCTD (grey circle) and delta yCTD (black circle) RPB1. (B)
Western analysis of whole cell lysates demonstrates expression of
tagged RPB1s. Phosphorylated and non-phosphorylated forms of
RPB1 are present. Anti-yCTD antibody (top panel) detects the
tagged version of the full yCTD and 2/3 yCTD, along with
endogenous RPB1. Anti-tag (Ty1) BB2 antibody (bottom panel)
detects only tagged-RPB1. Whereas the phosphorylated and non-
phosphorylated forms of full yCTD or 2/3 yCTD are visible,
only the non-phosphorylated forms of 1/3 yCTD or delta- yCTD
are detected.
Found at: doi:10.1371/journal.pone.0006959.s001 (0.39 MB
PDF)
Acknowledgments
We thank David Lukac and Karl Drlica for critical reading of the
manuscript. We gratefully appreciate the figure illustrations by Timothy
Linteau.
Author Contributions
Conceived and designed the experiments: AD VB. Performed the
experiments: AD VB. Analyzed the data: AD VB. Contributed reagents/
materials/analysis tools: AD. Wrote the paper: AD VB.
References
1. Cramer P, Armache KJ, Baumli S, Benkert S, Brueckner F, et al. (2008)
Structure of eukaryotic RNA polymerases. Annu Rev Biophys 37: 337–352.
2. Allison LA, Moyle M, Shales M, Ingles CJ (1985) Extensive homology among
the largest subunits of eukaryotic and prokaryotic RNA polymerases. Cell 42:
599–610.
3. Corden JL, Cadena DL, Ahearn JM, Jr., Dahmus ME (1985) A unique structure
at the carboxyl terminus of the largest subunit of eukaryotic RNA polymerase II.
Proc Natl Acad Sci U S A 82: 7934–7938.
4. Egloff S, Murphy S (2008) Cracking the RNA polymerase II CTD code. Trends
Genet 24: 280–288.
5. Buratowski S (2003) The CTD code. Nat Struct Biol 10: 679–680.
6. Phatnani HP, Greenleaf AL (2006) Phosphorylation and functions of the RNA
polymerase II CTD. Genes Dev 20: 2922–2936.
7. Palancade B, Bensaude O (2003) Investigating RNA polymerase II carboxyl-
terminal domain (CTD) phosphorylation. Eur J Biochem 270: 3859–3870.
8. Sims RJ, 3rd, Belotserkovskaya R, Reinberg D (2004) Elongation by RNA
polymerase II: the short and long of it. Genes Dev 18: 2437–2468.
9. Meinhart A, Kamenski T, Hoeppner S, Baumli S, Cramer P (2005) A structural
perspective of CTD function. Genes Dev 19: 1401–1415.
10. Stiller JW, Duffield EC, Hall BD (1998) Amitochondriate amoebae and the
evolution of DNA-dependent RNA polymerase II. Proc Natl Acad Sci U S A 95:
11769–11774.
11. Dacks JB, Marinets A, Ford Doolittle W, Cavalier-Smith T, Logsdon JM, Jr.
(2002) Analyses of RNA Polymerase II genes from free-living protists: phylogeny,
long branch attraction, and the eukaryotic big bang. Mol Biol Evol 19: 830–840.
12. Schumacher MA, Lau AO, Johnson PJ (2003) Structural basis of core promoter
recognition in a primitive eukaryote. Cell 115: 413–424.
13. Guo Z, Stiller JW (2004) Comparative genomics of cyclin-dependent kinases
suggest co-evolution of the RNAP II C-terminal domain and CTD-directed
CDKs. BMC Genomics 5: 69.
14. Gilinger G, Bellofatto V (2001) Trypanosome spliced leader RNA genes contain
the first identified RNA polymerase II gene promoter in these organisms. Nucl
Acids Res 29: 1556–1564.
15. Smith JL, Levin JR, Ingles CJ, Agabian N (1989) In trypanosomes the homolog
of the largest subunit of RNA Polymerase II Is encoded by two genes and has a
highly unusual C-terminal domain structure. Cell 56: 815–827.
16. Grondal EJM, Evers R, Kosubek K, Cornelissen AWCA (1989) Characteriza-
tion of the RNA polymerases of Trypanosoma brucei: trypanosomal mRNAs are
composed of transcripts derived from both RNA polymerase II and III. EMBO J
8: 3383–3389.
17. Yurchenko VY, Lukes J, Jirku M, Zeledon R, Maslov DA (2006) Leptomonas
costaricensis sp. n. (Kinetoplastea: Trypanosomatidae), a member of the novel
phylogenetic group of insect trypanosomatids closely related to the genus
Leishmania. Parasitology 133: 537–546.
18. Patrick KL, Luz PM, Ruan JP, Shi H, Ullu E, et al. (2008) Genomic
rearrangements and transcriptional analysis of the spliced leader-associated
retrotransposon in RNA interference-deficient Trypanosoma brucei. Mol
Microbiol 67: 435–447.
19. Thomas S, Green A, Sturm NR, Campbell DA, Myler PJ (2009) Histone
acetylations mark origins of polycistronic transcription in Leishmania major.
BMC Genomics 10: 152.
20. Chapman AB, Agabian N (1994) Trypanosoma brucei RNA Polymerase II Is
Phosphorylated in the Absence of Carboxyl-Terminal Domain Heptapeptide
Repeats. J Biol Chem 269: 4754–4760.
21. Das A, Li H, Liu T, Bellofatto V (2006) Biochemical characterization of
Trypanosoma brucei RNA polymerase II. Mol Biochem Parasitol 150: 201–210.
22. Devaux S, Lecordier L, Uzureau P, Walgraffe D, Dierick JF, et al. (2006)
Characterization of RNA polymerase II subunits of Trypanosoma brucei. Mol
Biochem Parasitol 148: 60–68.
23. Chapman RD, Palancade B, Lang A, Bensaude O, Eick D (2004) The last CTD
repeat of the mammalian RNA polymerase II large subunit is important for its
stability. Nucleic Acids Res 32: 35–44.
24. Chapman RD, Conrad M, Eick D (2005) Role of the mammalian RNA
polymerase II C-terminal domain (CTD) nonconsensus repeats in CTD stability
and cell proliferation. Mol Cell Biol 25: 7665–7674.
25. Lustig Y, Sheiner L, Vagima Y, Goldshmidt H, Das A, et al. (2007) Spliced-
leader RNA silencing: a novel stress-induced mechanism in Trypanosoma
brucei. EMBO Rep 8: 408–413.
26. Saunders A, Core LJ, Lis JT (2006) Breaking barriers to transcription elongation.
Nat Rev Mol Cell Biol 7: 557–567.
27. Smith ER, Winter B, Eissenberg JC, Shilatifard A (2008) Regulation of the
transcriptional activity of poised RNA polymerase II by the elongation factor
ELL. Proc Natl Acad Sci U S A 105: 8575–8579.
28. Wickstead B, Ersfeld K, Gull K (2002) Targeting of a tetracycline-inducible
expression system to the transcriptionally silent minichromosomes of Trypano-
soma brucei. Mol Biochem Parasitol 125: 211–216.
29. Wirtz E, Leal S, Ochatt C, Cross GA (1999) A tightly regulated inducible
expression system for conditional gene knock-outs and dominant-negative
genetics in Trypanosoma brucei. Mol Biochem Parasitol 99: 89–101.
30. Bastin P, Bagherzadeh Z, Matthews KR, Gull K (1996) A novel epitope tag
system to study protein targeting and organelle biogenesis in Trypanosoma brucei.
Mol Biochem Parasitol 77: 235–239.
31. Das A, Zhang Q, Palenchar JB, Chatterjee B, Cross GAM, et al. (2005)
Trypanosomal TBP functions with the multisubunit transcription factor tSNAP
to direct Spliced leader RNA gene expression. Mol Cell Biol 25: 7314–7322.
32. Sambrook J, Russell DW (2001) Molecular Cloning. Cold Spring Harbor: Cold
spring Harbor Laboratory press.
33. Ullu E, Tschudi C (1990) Permeable trypanosome cells as a model system for
transcription and trans-splicing. Nucleic Acids Res 18: 3319–3326.
34. Bangs JD, Crain PF, Hashizume T, McCloskey JA, Boothroyd JC (1992) Mass
spectrometry of mRNA cap 4 from trypanosomatids reveals two novel
nucleosides. J Biol Chem 267: 9805–9815.
35. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment through sequence
weighting, position-specific gap penalties and weight matrix choice. Nucleic
Acids Res 22: 4673–4680.
Non-Canonical CTD in T. brucei
PLoS ONE | www.plosone.org 10 September 2009 | Volume 4 | Issue 9 | e6959